CN109641058A - 治疗胰腺癌的组合疗法 - Google Patents

治疗胰腺癌的组合疗法 Download PDF

Info

Publication number
CN109641058A
CN109641058A CN201780051187.XA CN201780051187A CN109641058A CN 109641058 A CN109641058 A CN 109641058A CN 201780051187 A CN201780051187 A CN 201780051187A CN 109641058 A CN109641058 A CN 109641058A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
inhibitor
cancer
mek inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780051187.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.塞特尔曼
N.萨胡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN109641058A publication Critical patent/CN109641058A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201780051187.XA 2016-08-23 2017-08-22 治疗胰腺癌的组合疗法 Pending CN109641058A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378322P 2016-08-23 2016-08-23
US62/378322 2016-08-23
PCT/US2017/047985 WO2018039211A1 (en) 2016-08-23 2017-08-22 Combination therapy for the treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
CN109641058A true CN109641058A (zh) 2019-04-16

Family

ID=59762090

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051187.XA Pending CN109641058A (zh) 2016-08-23 2017-08-22 治疗胰腺癌的组合疗法

Country Status (11)

Country Link
US (2) US10933058B2 (enExample)
EP (1) EP3503922B1 (enExample)
JP (2) JP7579636B2 (enExample)
KR (1) KR20190039951A (enExample)
CN (1) CN109641058A (enExample)
AU (1) AU2017316618A1 (enExample)
BR (1) BR112019002945A2 (enExample)
CA (1) CA3034259A1 (enExample)
IL (1) IL264589A (enExample)
MX (1) MX2019002121A (enExample)
WO (1) WO2018039211A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115243719A (zh) * 2020-03-06 2022-10-25 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034259A1 (en) * 2016-08-23 2018-03-01 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer
WO2020014650A1 (en) * 2018-07-13 2020-01-16 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer
EP4048271A4 (en) * 2019-10-22 2023-10-04 Chemistryrx Methods for treating congenital epidermal hyperplasia
CN116509852A (zh) * 2023-04-30 2023-08-01 兰州大学第二医院 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用
CN116585312A (zh) * 2023-04-30 2023-08-15 兰州大学第二医院 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517548A (zh) * 2013-09-05 2016-04-20 豪夫迈·罗氏有限公司 用于治疗过度增生性病症的mek抑制剂和erk抑制剂的组合
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016123054A2 (en) * 2015-01-26 2016-08-04 The University Of North Carolina At Chapel Hill Kinase drug combinations and methods of use thereof
CA3034259A1 (en) * 2016-08-23 2018-03-01 Genentech, Inc. Combination therapy for the treatment of pancreatic cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105517548A (zh) * 2013-09-05 2016-04-20 豪夫迈·罗氏有限公司 用于治疗过度增生性病症的mek抑制剂和erk抑制剂的组合
WO2016130917A1 (en) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Synergistic cancer treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HO-JUNELEE等: "Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells", 《CANCER CELL》 *
MELISSA R. JUNTTILA等: "Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer", 《MOLECULAR CANCER THERAPEUTICS》 *
韩磊等主编: "《临床常见肿瘤疾病诊断与治疗 下》", 30 April 2016 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115243719A (zh) * 2020-03-06 2022-10-25 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用

Also Published As

Publication number Publication date
JP7579636B2 (ja) 2024-11-08
AU2017316618A1 (en) 2019-02-07
US20190175576A1 (en) 2019-06-13
US20210283120A1 (en) 2021-09-16
CA3034259A1 (en) 2018-03-01
US10933058B2 (en) 2021-03-02
JP2024170398A (ja) 2024-12-10
EP3503922A1 (en) 2019-07-03
BR112019002945A2 (pt) 2019-05-21
IL264589A (en) 2019-02-28
WO2018039211A1 (en) 2018-03-01
MX2019002121A (es) 2019-08-12
JP2019526559A (ja) 2019-09-19
US12419879B2 (en) 2025-09-23
KR20190039951A (ko) 2019-04-16
EP3503922B1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
Patel et al. Resistance to molecularly targeted therapies in melanoma
CN109641058A (zh) 治疗胰腺癌的组合疗法
New et al. Secretory autophagy in cancer-associated fibroblasts promotes head and neck cancer progression and offers a novel therapeutic target
Sachdeva et al. ID1 is critical for tumorigenesis and regulates chemoresistance in glioblastoma
Rager et al. Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies
Hashimoto et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
Sharma et al. Targeting CXCR2 enhances chemotherapeutic response, inhibits mammary tumor growth, angiogenesis, and lung metastasis
Naser et al. Role of the tumor microenvironment in cancer hallmarks and targeted therapy
Fenn et al. Phase 1 study of erlotinib and metformin in metastatic triple-negative breast cancer
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
US20140348819A1 (en) Methods of Treating Cancer
Lin et al. Ibrutinib potentiates antihepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma
JP2016204365A (ja) Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物
Zhang et al. SEMA3C supports pancreatic cancer progression by regulating the autophagy process and tumor immune microenvironment
Piao et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas
Kis et al. In Vivo Molecular Imaging of the Efficacy of Aminopeptidase N (APN/CD13) Receptor Inhibitor Treatment on Experimental Tumors Using 68Ga‐NODAGA‐c (NGR) Peptide
Nam et al. Integrin αvβ3 upregulation in response to nutrient stress promotes lung cancer cell metabolic plasticity
Hamilton et al. Overcoming resistance in small-cell lung cancer
Jin et al. Cinchona alkaloid-inspired urea-containing autophagy inhibitor shows single-agent anticancer efficacy
US11813305B2 (en) Endoplasmic reticulum stress as a predictive tool in cancer therapy and a combination therapy for the treatment of cancer
KR20230029360A (ko) C19를 포함하는 암 치료 효과 증진용 조성물 및 이의 용도
Li Notch1 signaling plays an essential role in metabolic rewiring in chemoresistance prostate cancer
Li et al. Attenuated Salmonella Carrying IL-21-siRNA-CCR2 Co-expression Plasmid Enhances Anti-tumor Immune Response in Lung Cancer-bearing Mice
HK40001148A (en) Combination therapy for the treatment of pancreatic cancer
Campos-Parra et al. Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanisms of Action Through in Vitro and in Vivo Analyses. Lausanne: Frontiers Media SA. doi: 10.3389

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190830

Address after: Basel, Switzerland

Applicant after: F. HOFFMANN-LA ROCHE AG

Address before: California, USA

Applicant before: Genentech, Inc.

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001148

Country of ref document: HK